ReviewTranslational cancer research2019
Invasive mucinous adenocarcinoma of the lung.
Review in Translational cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 43 citations in OpenAlex.
- CT Radiomics Combined With Clinicopathological Features to Predict Invasive Mucinous Adenocarcinoma in Patients With Lung Adenocarcinoma.Technology in cancer research & treatmentTrial
- Integrating multimodal data for precise subtyping and prognostication in patients with pulmonary mucinous adenocarcinoma.Translational cancer research · 2026Article
- A 45-Year-Old Woman With a Persistent Cavitary Consolidation.CHEST pulmonary · 2026Article
- Invasive mucinous adenocarcinoma of the lung: integrating molecular landscape, imaging phenotypes, and translational therapeutic strategies.Translational lung cancer research · 2026Review
- Immune checkpoint inhibitors for invasive mucinous adenocarcinoma: A case series.Oncology letters · 2026Article
- Molecular characteristics, clonal relatedness and surgical outcomes of pulmonary mixed invasive mucinous and non-mucinous adenocarcinoma: a retrospective cohort study.Molecular biomedicine · 2026Article
- Prognostic value of integrated FDG PET/CT avidity and CT morphologic subtypes in invasive mucinous adenocarcinoma of the lung.Annals of nuclear medicine · 2026Article
- What we can learn from the lepidic growth pattern of pulmonary metastases.Clinical & experimental metastasis · 2026Review
- Bilateral pulmonary cavitary mucinous adenocarcinoma in an immunocompetent patient: a case report and literature review.BMC pulmonary medicine · 2025Review
- Diagnostic utility of cryobiopsy for invasive mucinous lung adenocarcinoma.Translational lung cancer research · 2025Article
- Bilateral orthotopic lung transplantation for the patient with lung-limited invasive mucinous adenocarcinoma: a case-based literature review.The oncologist · 2025Review
- Survival Outcomes of Lung Adenocarcinoma With Intestinal Differentiation in the Era of Immunotherapy.JTO clinical and research reports · 2025Article
- High-accuracy prediction of mutations in nine genes in lung adenocarcinoma via two-stage multi-instance learning on large-scale whole-slide images.Diagnostic pathology · 2025Article
- Demographic and prognostic factors affecting survival in invasive mucinous adenocarcinoma: a national cancer database analysis.Medical oncology (Northwood, London, England) · 2025Article
- Sotorasib resistance in KRAS G12C-mutant invasive mucinous adenocarcinoma with implications for VEGF-A.NPJ precision oncology · 2025Article
- Case Report: Do not diagnose lung cancer as pneumonia: continue to monitor a case of invasive mucinous adenocarcinoma as it progresses from small to large.Frontiers in medicine · 2025Article
- Nomogram model for the diagnosis of solitary nodular pulmonary mucinous adenocarcinoma.Scientific reports · 2024Article
- Radiological Features of Primary Pulmonary Invasive Mucinous Adenocarcinoma Based on 312 Consecutive Patients.The clinical respiratory journal · 2024Article
- Concomitance of Pericardial Tamponade and Pulmonary Embolism in an Invasive Mucinous Lung Adenocarcinoma with Atypical Presentation: Diagnostic and Therapeutic Pitfalls-Case Report and Literature Review.International journal of molecular sciences · 2024Review
- Establishment and verification of novel TNM staging system for lung mucinous adenocarcinoma.BMC cancer · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive mucinous adenocarcinoma (IMA) is a unique histological subtype of adenocarcinoma. Due to its low incidence rates, survival data for IMA is scarce and often contradictory. The clinical manifestations of IMA are not precise as compared to other adenocarcinomas, with some patients having bronchial mucus overflow. Difference in immunohistochemical expression levels is present in IMA and invasive non-mucinous adenocarcinomas (INMA). Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are more frequent in IMAs, while epidermal growth factor receptor (EGFR) mutations are relatively rare. This makes it distinct from the other more common adenocarcinomas. Neuregulin 1 (NRG1) gene fusions are considered important therapeutic targets for IMA, suggesting that Afatinib may be an effective drug to treat IMA. However, IMA prognosis remains controversial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.